Way back in 2014-2015 during the design of BETonMACE, I think Resverlogix initially wanted to do a 5-point MACE CVOT in diabetics with rosuvastatin alone vs. rosuvastatin + apabetalone. But during discussions with the FDA, EMA, and Clinical Steering Committee, one or more of those parties strongly encouraged (demanded?/required?) that BETonMACE be 3-point MACE CVOT and include both atorvastatin and rosuvastatin groups.